Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study

Juan M. Cano-Calderón, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Juan F. Zazueta-Pozos, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Adán G. Gallardo-Rodríguez, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Carlos Martínez-Murillo, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Irma Olarte-Carrillo, Molecular Biology Laboratory, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Adolfo Martínez-Tovar, Molecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, MexicoMolecular Biology Laboratory, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Christian O. Ramos-Peñafiel, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico